Biomedical Occupation or Discipline
Surrozen sets its sights on ophthalmology after binning liver programme
Ophthalmology specialty, Severe (severity modifier)
Trump Administration Considers Cuts to CDC’s HIV Prevention Program, Raising Concerns
HIV prevention, CDC funding cuts, Trump administration, public health, HIV/AIDS advocacy
MeiraGTx and Hologen AI Form $430M Collaboration to Advance Parkinson’s Gene Therapy
gene therapy, Parkinson’s disease, artificial intelligence, clinical trials, biotechnology partnership
Pharmaceutical Giants Mallinckrodt and Endo Explore $7 Billion Merger
Pharmaceutical merger, Mallinckrodt, Endo, $7 billion deal, Specialty pharmaceutical companies, Post-bankruptcy consolidation, Opioid crisis fallout
On the heels of FDA nod for cancer drug, Sun Pharma buys Checkpoint Therapeutics for up to $416M
UNLOXCYT, Checkpoint Therapeutics, Squamous cell carcinoma of skin, United States Food and Drug Administration, Sun Pharma
Nimbus Therapeutics Announces Leadership Transition: Abbas Kazimi Appointed as New CEO
Nimbus Therapeutics, CEO transition, Abbas Kazimi, Jeb Keiper, biotechnology, computational drug discovery
Acelyrin Rebuffs Concentra’s Acquisition Bid, Reaffirms Commitment to Alumis Merger
Acelyrin, Concentra Biosciences, Alumis, Merger, Acquisition offer, Immunology, Biopharmaceuticals, All-stock transaction
Callio Therapeutics Debuts with $187M to Develop Next-Generation Multi-Payload ADCs for Cancer
Multi-payload ADCs, antibody-drug conjugates, oncology, HER2-targeted therapy, dual-payload technology, cancer treatment, biotechnology startup
The Perfect Storm: Why 2025 Will Be the Year of GxP AI in Pharma
GxP AI, pharmaceutical manufacturing, regulatory compliance, data-driven innovation, quality management, drug development
Eli Lilly Partners with Magnet Biomedicine in $1.25B Molecular Glue Deal
Eli Lilly, Magnet Biomedicine, molecular glue, drug discovery, oncology, collaboration